 |
|
 |
Diseases |
|
|
Therapeutics for Inflammatory Diseases
Current Challenges and Future Market
Publication Date March 2006
Publisher Business Communications Company
Product Type Report
Pages 183
ISBN Number not applicable
Product Code BCC031
|
|
|
Summary
The anti-inflammatory products market was dramatically shaken in September 2004 with the withdrawal from the marketplace of Merck's multibillion-dollar anti-inflammatory drug Vioxx. This was followed by the withdrawal of another cyclooxygenase-2 (COX-2) inhibiting anti-inflammatory product, Pfizer's Bextra, from the American, Canadian and European markets in April 2005. This left only one COX-2 inhibitor, Pfizer's Celebrex, on the U.S. market. Following the removal of Vioxx, the U.S. Food and Drug Administration (FDA) enhanced its scrutiny of this class of drugs and required black-box warnings to be placed on all similar prescription and nonprescription nonsteroidal anti-inflammatory drugs (NSAIDs).
Scope Of Study
This comprehensive study:
- Analyzes and assesses marketed and in-development prescription, systemic anti-infl ammatory drugs indicated for the following diseases-ankylosing spondylitis, asthma/chronic obstructive pulmonary disease (COPD), infl ammatory bowel diseases, multiple sclerosis, psoriasis and rheumatoid arthritis.
- Provides an overview of the categories of anti-inflammatory drugs, including biological anti-inflammatory products, their methods of activity, usage and sales. Markets for antiinfl ammatory drugs by disease, including sales and forecasts as well as discussion of products for each indication that are in Phase II and later trials.
- Discusses industry structure including the impact of the removal of Vioxx and Bextra from the marketplace. Also discussed is the issue of direct-to-consumer (DTC) marketing.
- Profiles companies emphasizing leaders in the pharmaceutical and biotechnology industry in the research and development of anti-inflammatory drugs and the innovative products they have launched or have in development.
Report Highlights
- The market for anti-inflammatory drugs to treat the diseases covered in this report was approximately $21.9 billion in 2005 and is projected to increase to $35.5 billion in 2010.
- The fastest growing disease category for anti-inflammatory treatment is psoriasis, which saw the first introductions of expensive monoclonal antibody products in the last two years.
- The largest market by far in 2005 is that for the treatment of asthma and chronic obstructive pulmonary disease, which accounted for approximately 36% of the total market in 2005. The asthma/COPD market will remain the largest in 2010, but will decline to 31.4% of the total of market by the end of the forecast period.
|
Content
- Introduction
- Study Goal And Objectives
- Reasons For Doing The Study
- Contribution Of The Study And For Whom
- Study Scope And Format
- Methodology
- Information Sources
- Analyst's Credentials
- Related BCC Work Credentials Including Work Done By Other Authors
- BCC Online Services
- Disclaimer
- Summary
- Summary Table: Global Market For Anti-Inflammatory Treatmentsby Type Of Diseases, Through 2010 ($ Millions)
- Summary Figure: Estimated Global Market Share For Anti-Inflammatory Treatments By Selected Diseases, 2005 And 2010 (%)
- Overview
- The Immune System And The Inflammatory Response
- Nonspecific Immunity
- Specific Immunity
- Cell-Mediated Immunity
- Humoral Immunity
- The Role Of Mediators In The Inflammatory Response
- Complement
- Complement Inhibitors In Development
- Cytokines
- Functions Of Cytokines
- Anti-Inflammatory Cytokines
- Two Categories Of Cytokines Involved In Inflammation
- Biological Response Modifiers
- Biological Response Modifiers Important To The Inflammatory Process
- Chemokines
- Interleukins
- Interleukin-2
- Other Infection-Fighting Cells
- Side Effects
- Tumor Necrosis Factor (TNF)
- Major Anti-Inflammatory Cytokines With Therapeutic Indications
- Il-1ra
- Il-4
- Il-6
- Il-10
- Il-11
- Il-13
- Tgf-ß
- Suppressors Of Cytokine Signaling
- Current Product Categories For Inflammatory Diseases
- Antibody-Based Products
- Antibodies In Development For The Treatment Of Inflammatory Diseases
- Drugs In Development For Inflammatory Diseases
- Targets For Anti-Inflammatory Drugs
- Nuclear Factor Kb
- Toll-Like Receptors
- Applications And Products
- Categories Of Prescription Anti-Inflammatory Products On The World Market
- Corticosteroids
- Disease-Modifying Antirheumatic Agents
- Immunomodulators
- The Market For Anti-Inflammatory Drugs By Category
- Nonsteroidal Anti-Inflammatory Drugs On The Market
- Cox-2 Inhibitors
- The Market For Cox-2 Inhibitors
- Next-Generation Cox-2 Inhibitors
- Biological Response Modifiers
- Il-1 Inhibitors
- Tumor Necrosis Factor Inhibitors
- Indications
- Ankylosing Spondylitis
- Anti-Inflammatory Drugs Approved For The Treatment Of Ankylosing Spondylitis
- The Market For Drugs To Treat Ankylosing Spondylitis
- Anti-Inflammatory Drugs In Development For The Treatment Of Ankylosing Spondylitis
- Humira
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- The Role Of Cytokines In Asthma
- Currently Marketed Products
- Anti-Inflammatory Drugs Used To Treat Asthma
- Corticosteroids
- Leukotriene Modifiers
- Ige Inhibitors
- Phosphodiesterase Inhibitors
- Mast-Cell Inhibitors
- Efficacy Of Available Drugs
- Top-Selling And Recently Introduced Anti-Inflammatory Products To Treat Asthma And Copd
- Advair/Seretide
- Alvesco
- Azmacort
- Singulair
- Xolair
- The Market For Anti-Inflammatory Drugs To Treat Asthma
- The Market For Anti-Inflammatory Drugs To Treat Copd
- Anti-Inflammatory Products In Development For The Treatment Of Asthma And Copd
- Adhesion Molecule Antagonists
- Cytokine Antagonists
- Ige Antagonists
- Oligonucleotide And Gene Therapies
- Phosphodiesterase Inhibitors
- Transcription-Factor Antagonists
- Tumor Necrosis Factor-Alpha Inhibitors
- 1018 Iss
- 159797
- 678007
- 685698
- 766994
- 799943
- Advair/Seretide And Serevent
- Ave 0675/Ave 7279
- Awd12-281
- Cat-354
- Cc-10004
- Daclizumab/R35
- Daxas
- Epi-12323
- Ic485
- Mepolizumab
- Nva237
- Ono-6126
- Pleconaril
- Qab149
- R411
- Xolair
- Technology Approaches To The Development Of New Anti-Inflammatory Drugs To Treat Asthma
- Inflammatory Bowel Diseases
- Crohn's Disease
- Irritable Bowel Syndrome
- Ulcerative Colitis
- Products Used To Treat Inflammatory Bowel Diseases
- Remicade
- Other Recently Introduced Products
- The Market For Drugs To Treat Inflammatory Bowel Disease
- Anti-Inflammatory Products In Development For The Treatment Of Inflammatory Bowel Diseases
- 270384
- 683699
- Alequel
- Alicaforsen
- Apaza
- Bms-561392
- Cilansetron
- Isis-104838
- Kappaproet
- Ldp-02
- Leukine
- Onercept
- Rdp58
- Renzapride
- Sta-5326
- Talnetant
- Teduglutide
- Antibody Products In Development For The Treatment Of Inflammatory Bowel Diseases
- Abt-874
- Cimzia
- Cnto 1275
- Humicade
- Humira
- Huzaf
- Leukine
- Mln02
- Nuvion
- Remicade
- Tysabri
- Biological Response Modifiers In Development Of The Treatment Of Crohn's Disease
- Multiple Sclerosis
- Marketed Anti-Inflammatory Products For The Treatment Of Multiple Sclerosis
- Cytokine-Based Products
- Avonex
- Betaseron
- Rebif
- Tysabri (Formerly Antegren)
- The Market For Anti-Inflammatory Drugs To Treat Multiple Sclerosis
- Anti-Inflammatory Drugs In Development For The Treatment Of Multiple Sclerosis
- Antibody-Based Products
- Other Products In Development
- Psoriasis
- Recently Introduced Anti-Inflammatory Treatments For Psoriasis
- Enbrel
- Raptiva
- Remicade
- Other Approved Biologic Products For The Treatment Of Psoriasis
- Amevive
- Other Anti-Inflammatory Drugs For The Treatment Of Psoriasis
- 6-Thioguanine
- Accutane
- Hydrea
- Isa247
- Mycophenolate Mofetil
- Ontak
- Sulfasalazine
- Phototherapy In The Treatment Of Psoriasis
- The Market For Anti-Inflammatory Drugs To Treat Psoriasis
- Products In Development For The Treatment Of Psoriasis
- Antibody Products In Development For The Treatment Of Psoriasis
- Other Anti-Inflammatory Products In Development For The Treatment Of Psoriasis
- Photodynamic Therapy (PDT) For The Treatment Of Psoriasis
- The Fda Approves Pdt
- Early Problems With Pdt
- Technology Breakthroughs In The 1980s
- Improved Photosensitizing Agents
- New Light Sources
- The Two Stages Of Pdt Treatment
- Choosing The Correct Wavelength
- The Role Of Singlet Oxygen
- Dual Control Mechanisms Of Pdt
- Mechanisms Of Pdt-Induced Cell Death
- Direct Cell Kill
- Indirect Cell Kill Via Vascular Damage
- Immunological Response Of Pdt
- Applications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Currently Available Treatments
- Antibody-Based Products
- Enbrel
- Humira/Trudexa
- Remicade
- Other Biological Products
- Kineret
- Tumor Necrosis Factor Inhibitors
- Cost Of Biological Agents To Treat Rheumatoid Arthritis
- Market Possibilities For Biologic Treatments
- The Market For Tnf-Alpha Inhibitors
- Other Products Used To Treat Arthritis
- Cox-2 Inhibitors
- Celebrex
- Mobic
- The Market For Anti-Inflammatory Drugs To Treat Rheumatoid Arthritis
- Products In Development To Treat Rheumatoid Arthritis
- Antimetabolites
- Chemotaxis Inhibitors
- Complement Inhibitors
- Cytokine Inhibitors
- Other Dmards In Development
- Antibody-Based Products
- Acz885
- Amg 108
- Amg 162
- Amg 714
- Anti-Cd20 (Second Generation)
- Arcoxia
- Bms-561392
- Cimzia
- Cnto 148
- Eculizumab
- Humax-Cd4
- Humax-Cd20
- Humira
- Il-1 Trap
- Il-18 Binding Protein
- Isis-104838
- Lymphostat-B
- Mln1202
- Orencia
- Pegstnf-Ri
- Pmi-005
- Prexige
- Pro70769
- R1569
- Remicade
- Rituxan/Mabthera
- Scio-323
- Scio-469
- Tenovil
- Industry
- The Vioxx Fallout
- Creating An Unwarranted Market?
- The Fda Takes A Hard Look At Direct-To-Consumer (DTC) Advertising
- Future Of Cox-2 Inhibitors
- The Effect Of Insurance Company Reimbursement
- Company Profiles
- Abbott Laboratories
- Business Overview
- Financial Information
- Products
- Corporate Strategy
- Alexion Pharmaceuticals, Inc.
- Business Overview
- Financial Information
- Product Candidates
- Company Strategy
- Altana Pharma Ag
- Business Overview
- Financial Information
- Products
- Corporate Strategy
- Amgen, Inc.
- Business Overview
- Financial Information
- Products
- Corporate Strategy
- Biogen Idec, Inc.
- Business Overview
- Financial Information
- Products
- Corporate Strategy
- Cambridge Antibody Technology Group Plc
- Business Overview
- Products
- Corporate Strategy
- Celgene Corporation
- Business Overview
- Products
- Financial Information
- Corporate Strategy
- Dynavax Technologies Corporation
- Business Overview
- Financial Information
- Products In Development
- Corporate Strategy
- Epigenesis Pharmaceuticals
- Business Overview
- Products In Development
- Corporate Strategy
- Genentech, Inc.
- Business Overview
- Financial Information
- Products
- Corporate Strategy
- Genmab A/S
- Business Overview
- Products
- Corporate Strategy
- Glaxosmithkline Plc
- Business Overview
- Financial Information
- Products
- Corporate Strategy
- Isis Pharmaceuticals, Inc.
- Business Overview
- Financial Information
- Products
- Corporate Strategy
- Millennium Pharmaceuticals, Inc.
- Business Overview
- Financial Information
- Products
- Corporate Strategy
- Novartis Ag
- Business Overview
- Financial Information
- Products
- Protein Design Labs
- Business Overview
- Financial Information
- Products
- Corporate Strategy
- Regeneron Pharmaceuticals, Inc.
- Business Overview
- Financial Information
- Product Candidates
- Corporate Strategy
- Schering-Plough Corporation
- Business Overview
- Financial Information
- Products
- Corporate Strategy
- List Of Figures
- Summary Table: Global Market For Anti-Inflammatory Treatmentsby Type Of Diseases, Through 2010 ($ Millions)
- Table 1 Mediators Of Inflammation And Their Function(S)
- Table 2 Complement Inhibitors In Development
- Table 3 Cytokines With Anti-Inflammatory Activity
- Table 4 Soluble Cytokine Receptors With Anti-Inflammatory Activity
- Table 5 Categories Of Cytokines
- Table 6 Colony Stimulating Factors And Erythropoietin, Their Natural Sources And Major Effects
- Table 7 Interferons, Their Natural Sources And Major Effects
- Table 8 Interleukins, Their Natural Sources And Major Effects
- Table 9 Tumor Necrosis Factors (TNFS), Their Natural Sources And Major Effects
- Table 10 Anti-Inflammatory Cytokines In Clinical Development
- Table 11 Suppressors Of Cytokine Signaling And Their Potential Therapeutic Areas
- Table 12 Marketed Monoclonal Antibody Products For The Treatment Of Anti-Inflammatory Diseases
- Table 13 Therapeutic Antibody Products In Phase Ii Or Later Development For The Treatment Of Inflammatory Diseases
- Table 14 Drugs In Phase Ii Or Later Development For The Treatment Of Inflammatory Diseases
- Table 15 Global Market For Anti-Inflammatory Treatments By Category, Through 2010 ($ Millions)
- Table 16 Currently Marketed Nonsteroidal Anti-Inflammatory Drugs
- Table 17 Global Market For Cox-2 Inhibitors By Product, Through 2010 ($ Millions)
- Table 18 U.S. Market For Cox-2 Inhibitors By Product, Through 2010 ($ Millions)
- Table 19 Global Market For Anti-Inflammatory Treatments For Ankylosing Spondylitis, Through 2010 ($ Millions)
- Table 20 Asthma Drug Categories And Selected Products
- Table 21 Selected Branded Anti-Inflammatory And Bronchodilating Drugs Used To Treat Asthma
- Table 22 Global Market For Asthma Drugs By Category, Through 2010 ($ Millions)
- Table 23 Global Market For Anti-Inflammatory Drugs Used To Treat Asthma By Category, Through 2010 ($ Millions)
- Table 24 U.S. Market For Asthma Drugs By Category, Through 2010 ($ Millions)
- Table 25 Global Market For Copd Drugs By Category, Through 2010 ($ Millions)
- Table 26 Global Market For Anti-Inflammatory Drugs Used To Treat Copd By Category, 2003-2010 ($ Millions)
- Table 27 Phosphodiesterase Inhibitors In Phase Ii Or Late Development
- Table 28 Targets And Approaches To The Development Of Anti- Inflammatory Drugs To Treat Asthma
- Table 29 Global Market For Anti-Inflammatory Treatments For Inflammatory Bowel Disease By Category, Through 2010 ($ Millions)
- Table 30 Biological Response Modifiers In Phase Ii Or Later Development For The Treatment Of Crohn's Disease
- Table 31 Global Market For Anticytokine Anti- Inflammatory Treatments For Multiple Sclerosis, Through 2010 ($ Millions)
- Table 32 Global Market For Anti-Inflammatory Treatments For Psoriasis, By Category, Through 2010 ($ Millions)
- Table 33 Commonly Used Dmards For The Treatment Of Rheumatoid Arthritis
- Table 34 Currently Available Biologic Products For The Treatment Of Rheumatoid Arthritis
- Table 35 Global Market For Marketed Tnf-Alpha Inhibiting Products For All Indications, Through 2010 ($ Millions)
- Table 36 Global Market For Anti-Inflammatory Treatments For Rheumatoid Arthritis By Category, Through 2010 ($ Millions)
- Table 37 Global Market For Anti-Inflammatory Treatments For Rheumatoid Arthritis By Region, Through 2010 ($ Millions)
- Table 38 Products In Phase Ii Or Later Development For The Treatment Of Rheumatoid Arthritis
- Table 39 Amgen's Anti-Inflammatory Product Pipeline
- Table 40 Biogen Idec's Anti-Inflammatory Product Pipeline
- Table 41 Cambridge Antibody Technology's Anti-Inflammatory Product Pipeline
- Table 42 Glaxosmithkline's Anti-Inflammatory Product Pipeline
- Table 43 Millennium's Anti-Inflammatory Monoclonal Antibody Product Pipeline
- Table 44 Protein Design Labs' Anti-Inflammatory Monoclonal Antibody Product Pipeline
- List Of Figures
- Summary Figure: Estimated Global Market Share For Anti-Inflammatory Treatments By Selected Diseases, 2005 And 2010 (%)
- Figure 1 Global Market For Anti-Inflammatory Treatments By Category, 2003-2010 ($ Millions)
- Figure 2 Global Market For Cox-2 Inhibitors By Product, 2003-2010 ($ Millions)
- Figure 3 U.S. Market For Cox-2 Inhibitors By Product, 2003-2010 ($ Millions)
- Figure 4 Global Market For Asthma Drugs By Category, 2003-2010 ($ Millions)
- Figure 5 Global Market For Anti-Inflammatory Drugs Used To Treat Asthma By Category, 2003-2010 ($ Millions)
- Figure 6 U.S. Market For Asthma Drugs By Category, 2003-2010 ($ Millions)
- Figure 7 Global Market For Copd Drugs By Category, 2003-2010 ($ Millions)
- Figure 8 Global Market For Anti-Inflammatory Drugs Used To Treat Copd By Category, 2003-2010 ($ Millions)
- Figure 9 Estimated Global Market Share For Anti-Inflammatory Drugs To Treat Asthma/Copd, By Category, 2005 And 2010 (%)
- Figure 10 Global Market For Anti-Inflammatory Treatments For Inflammatory Bowel Disease By Category, 2003-2010 ($ Millions)
- Figure 11 Global Market For Anti-Inflammatory Treatments For Psoriasis, By Category, Through 2010 ($ Millions)
- Figure 12 Categories Of Drugs Used In Conjunction With Tnf-Alpha Inhibitors (%)
- Figure 13 Global Market For Marketed Tnf-Alpha Inhibiting Products For All Indications, 2003-2010 ($ Millions)
- Figure 14 Global Market For Anti-Inflammatory Treatments For Rheumatoid Arthritis By Category, 2003-2010 ($ Millions)
- Figure 15 Global Market For Anti-Inflammatory Treatments For Rheumatoid Arthritis By Region, 2003-2010 ($ Millions)
- Figure 16 Estimated Global Prescription Market Share For Anti-Inflammatory Treatments For Rheumatoid Arthritis, By Category, 2005 (%)
|
|
|
